Related Experiment Video
Updated: May 30, 2026
Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights
Published on: October 13, 2023
Evaluation of disease severity in mucopolysaccharidoses
Michael Beck1, Joseph Muenzer, Maurizio Scarpa
1Children's Hospital, University of Mainz, Mainz, Germany.
Abstract:
The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders characterized by a wide variation in symptoms and progression rates. Each of the MPS types is caused by a deficiency in one of the enzymes involved in the catabolic pathway of glycosaminoglycans. MPS are usually suspected on the basis of the concomitant presence of several typical features of the disease, such as short stature, coarse facial features, loss of hearing, bone deformities, joint stiffness, organomegaly, respiratory and cardiovascular complications, and, in some cases, developmental delay. Very reduced or absent enzyme activity is required to confirm an MPS diagnosis. In the past, treatment of MPS was limited to the management of individual symptoms of the diseases. Currently, specific therapies such as hematopoietic stem cell transplantation and enzyme replacement therapy have improved the outlook for many MPS patients. To monitor disease progression and the impact of therapy in these patients, there is need for a validated scoring system for evaluating disease severity in MPS. A scoring system should take into account all aspects of MPS, particularly quality of life and functioning of arms, hands and legs and related mobility, endurance, self care and social functioning. This paper discusses several of the available scoring systems for bone/skeletal disorders and their potential usefulness in patients with MPS.
Insights
Mucopolysaccharidoses (MPS) are rare genetic disorders. This study reviews scoring systems to assess MPS severity, focusing on quality of life and physical function to guide treatment.
Area of Science:
- Biochemistry and Genetics
- Rare Diseases
- Lysosomal Storage Disorders
Background:
- Mucopolysaccharidoses (MPS) are a group of inherited lysosomal storage disorders.
- Caused by enzyme deficiencies in glycosaminoglycan metabolism, MPS presents with diverse symptoms like skeletal deformities and organomegaly.
- Current treatments include hematopoietic stem cell transplantation and enzyme replacement therapy.
Purpose of the Study:
- To address the need for a validated scoring system to evaluate disease severity in MPS patients.
- To consider quality of life and functional aspects, including mobility and self-care, in assessing MPS.
- To discuss the potential utility of existing skeletal disorder scoring systems for MPS.
Main Methods:
- Review of available scoring systems for bone and skeletal disorders.
- Evaluation of their applicability to the multifaceted nature of MPS.
- Consideration of key assessment domains: quality of life, physical function, and social impact.
Main Results:
- Existing scoring systems for skeletal disorders may offer a basis for MPS assessment.
- A comprehensive scoring system for MPS should integrate various clinical and functional parameters.
- Further validation is needed to tailor existing systems or develop new ones for MPS.
Conclusions:
- A validated scoring system is crucial for monitoring MPS progression and treatment efficacy.
- Such a system must encompass a holistic view of the patient, including functional status and quality of life.
- This review highlights the potential of existing tools and the need for specialized MPS scoring systems.
More Related Videos
Related Concept Videos
01:23Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
01:22Lysosomal Hydrolases